financetom
Business
financetom
/
Business
/
Saputo Reports Higher Q1 Adjusted Profit, Revenue up Near 10%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Saputo Reports Higher Q1 Adjusted Profit, Revenue up Near 10%
Aug 8, 2024 3:22 PM

05:57 PM EDT, 08/08/2024 (MT Newswires) -- Saputo ( SAPIF ) on Thursday reported higher adjusted profit and revenue in the first quarter.

The dairy and cheese products company said adjusted net earnings rose 8.4% to $167 million, or $0.39 per share, from $154 million or $0.36 per share.

Revenue of $4.6 billion, was 9.5% higher than the $4.2 billion booked last year. The company said the higher revenue was due to higher sales volumes across the board.

Saputo ( SAPIF ) announced a 2.7% dividend increase, to $0.19 per share, payable on September 20.

Shares closed $0.86 higher, to $31.56 on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Montrose Environmental Acquires Canada-based Paragon Soil & Environmental Consulting
Montrose Environmental Acquires Canada-based Paragon Soil & Environmental Consulting
Jun 5, 2024
08:25 AM EDT, 06/05/2024 (MT Newswires) -- Montrose Environmental Group ( MEG ) said Wednesday that it has acquired Paragon Soil & Environmental Consulting, a Canada-based environmental consulting firm. Financial terms of the deal were not disclosed. Price: 43.54, Change: -0.43, Percent Change: -0.98 ...
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug
Jun 5, 2024
08:25 AM EDT, 06/05/2024 (MT Newswires) -- Mind Medicine's (MNMD) shares were down 9% in Wednesday's premarket activity, a day after advisers to the US Food and Drug Administration voted against Lykos Therapeutics' psychedelic drug. Lykos Therapeutics said late Tuesday that advisers to the US Food and Drug Administration have voted against its therapy based on the mind-altering drug midomafetamine,...
Calibre Reports Additional Gold Mineralization at Valentine Gold Mine Complex in Newfoundland & Labrador
Calibre Reports Additional Gold Mineralization at Valentine Gold Mine Complex in Newfoundland & Labrador
Jun 5, 2024
08:26 AM EDT, 06/05/2024 (MT Newswires) -- Calibre (CXB.TO), which lost 4% yesterday, on Wednesday highlighted drill results from its 2024 exploration program within its 250-square-kilometer Valentine Gold Mine complex in Newfoundland & Labrador, Canada. Among the highlights, the company reported 2.25 g/t of gold over 15.30 meters estimated true width, including 24.68 g/t of gold over 0.85 meters estimated...
Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories
Axsome Therapeutics Says It Settled Sunosi Patent Litigation With Unichem Laboratories
Jun 5, 2024
08:27 AM EDT, 06/05/2024 (MT Newswires) -- Axsome Therapeutics ( AXSM ) said Wednesday it has settled patent litigation with Unichem Laboratories regarding Axsome's sleep disorder drug Sunosi. The pharmaceutical company said the litigation, pending in the United States District Court for the District of New Jersey, arose after Unichem applied for the US Food and Drug Administration's approval to...
Copyright 2023-2025 - www.financetom.com All Rights Reserved